Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | PTPRC | P08575 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | S100A4 | P26447 | 3/20 | 0.59 |
| ▸ | APAF1 | O14727 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | GALK1 | P51570 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029304 | 0.95 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1143212 | 0.86 | ALDH1A1 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL3698733 | 0.86 | MCL1 (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL14629464 | 0.86 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL12124166 | 0.82 | PTK2 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL8205250 | 0.81 | MCL1 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL30804365 | 0.80 | ALDH1A1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL8777800 | 0.80 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL30804366 | 0.80 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL8770711 | 0.80 | ALDH1A1 (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108504089-B | High-strength wear-resistant plastic material and preparation method thereof | 深圳市华万彩实业有限公司 | 2020-12-18 | — | — | CN | claimed |
| CN-108504089-B | High-strength wear-resistant plastic material and preparation method thereof | 深圳市华万彩实业有限公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-1309563-B1 | HETEROCYCLIC-HYDROXYIMINO-FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES | AGOURON PHARMA (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1309563-A1 | HETEROCYCLIC-HYDROXYIMINO-FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES | Agouron Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6462060-B2 | MEDIATING TYROSINE KINASE SIGNAL TRANSDUCTION; TREATING TUMOR GROWTH, CELL PROLIFERATION, OR ANGIOGENESIS | AGOURON PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020049238-A1 | Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CHONG WESLEY KWON MUNG (US) | 2002-04-25 | — | — | US | disclosed |
| WO-2002016326-A1 | HETEROCYCLIC-HYDROXYIMINO-FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049238-A1 | Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CHUK, BRAF, UACA | NPC1 3322/4885RAB9A 2145/4885SMN1; SMN2 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.